Cristina Saura, MD, on Breast Cancer: Results from the LORELEI Trial

Posted: Tuesday, September 12, 2017

Cristina Saura, MD, of Vall d’Hebron Institute of Oncology, discusses phase II study findings on neoadjuvant letrozole plus taselisib vs letrozole plus placebo in postmenopausal patients with ER+/HER2– early breast cancer.